“It is not a bad idea to talk about product research and development, not to talk about market development.†At the “Healthy China 2020 Strategic Plan†national medical industry policy seminar yesterday, veterans from more than 30 well-known pharmaceutical companies in the country were very optimistic about the prospects for the development of ethnic medicine in Yunnan. , and one after another for Yunyao secondary entrepreneurial tricks.
“For instance, Lao Dian Yun Tang has a long history, but the company only has more than 200 people. The human resources in marketing are obviously insufficient. The national culture is not well integrated with the national drug marketing. These long history and moving stories can be used for marketing packaging. Tao Zhaohui, assistant to president of Shanghai Fosun Pharmaceutical Group Co., Ltd., believes.
Yunnan ethnic pharmaceutical companies also took the opportunity to “throw the ball of hydrangeaâ€, and some companies also showed their intention of further cooperation.
There is a lack of clustering effect of Yunyao medicine. “The development of natural plant medicines in the world is in the ascendant, and the global market for natural botanical medicines is growing at a rate of 20% every year. This is a good opportunity for Yunyao's “Quick Horseâ€. More than 5,000 of the country’s production Among the kinds of drugs, there are more than 3,500 species involved in Yunnan botanical raw materials. Yunnan has a clear advantage in the development of botanical drug industry, and natural medicines based on plant extracts are the most potential and competitive advantages of Yunyao Pharmaceuticals. Direction.†Sun Xueming, director of Yunnan Food and Drug Administration, said.
The number of medicinal resources in Yunnan ranks first in the country, laying a good foundation for Yunnan's development of a cloud-drug industry dominated by natural medicine. At present, the rapid development of pharmaceutical industry and biomedical development in Yunnan Province, Yunnan Baiyao series, Panax notoginseng saponins series, artemisinin and artemether series, breviscapine series products, have a great impact in the country.
However, serious shortage of R&D investment, shortage of talents, irrational structure, severely lagging in standard research, and severe destruction of natural medicine resources are the most pressing difficulties for the development of cloud pharmaceutical industry. In particular, the corporate structure is irrational, polarization is severe, and profitability is low. Most enterprises are in a state of slight surplus or loss.
Up till now, only the production value of Yunnan Baiyao Group Co., Ltd. has reached a level of RMB 1 billion in the entire cloud pharmaceutical industry, and there are only five Yunpu Pharmaceutical manufacturers with an output value of RMB 200 million. In general, the status of the cloud pharmaceutical industry can be attributed to being small, scattered, weak, and miscellaneous. The degree of concentration is not high. There is no scale, no manifestation of the effectiveness of the cluster is the current "killing injury" cloud medicine. Take Xiong Yao as an example, the total amount of Chuxiong's natural medicine industry is small, and its industrial support ability is weak. The capacity for independent innovation is weak, and there are fewer independent branded products. In addition to the detoxification and nourishing capsules, there is not a batch of brands with good economic benefits.
The 20 billion target was initially set to expand and strengthen the cloud pharmaceutical industry, turning its resource advantage into a market advantage. Yunnan proposed to build the cloud pharmaceutical industry as if it were building a cloud tobacco industry. According to the development goals of Yunyao Pharmaceutical, by 2012, Yunpai will achieve a production value of over 20 billion yuan and become the most promising pillar industry.
How to divide cloud medicine cake? More than 70% of the province's pharmaceutical industry gathers in Kunming. The leading pharmaceutical companies in the province are highly concentrated. Based on this, Kunming City pioneered the clarion call of the “second venture†of the Yunyao Pharmaceutical Industry and proposed that by 2020, it will build the pharmaceutical industry into Kunming’s most important high-tech industry and become the country’s most distinctive pharmaceutical industry base; by 2012 We will strive to nurture 10 single-products with annual sales income of over 100 million yuan and 10 national and provincial-level well-known pharmaceutical brands. In this way, by 2012, Kunming plans to cultivate at least two pharmaceutical companies with sales revenues of more than 3 billion yuan each year, and more than five pharmaceutical companies with sales revenue exceeding one billion yuan, and 30 companies with sales revenue exceeding one hundred million yuan.
With the cultivation area of ​​31,230 mu of traditional Chinese medicinal materials and 964.07 tons of traditional Chinese medicine, Chuxiong is not far behind. After four years, it will use four years of time to attract investment, enrich the production and processing capacity of the pharmaceutical industry, and establish a brand name of “Sao Yaoâ€. Fully integrated into the “Sino-Indonesia Chinese Medicine Industry Beltâ€, it will eventually become the sub-center and core area of ​​the Suizhong Belt, and by 2020 it will reach a scale of more than 10 billion yuan, becoming a “hometown of drugs†and a traditional Chinese medicine valley.
"National Card" will become a breakthrough and the "national card" is the unique development direction of Yunnan. Yunnan has a large number of ethnic groups and has gradually formed a unique Yunyao culture system that is supplemented by minority medicine, Hanzi Tibetan medicine, and Miao Zhuang Naxi. There are more than 1,300 kinds of medicinal materials recorded by various ethnic groups and more than 10,000 non-governmental prescriptions. Many of them have unique features and are the source of new drug research and development. Digging, sorting, and developing national medicines will create a unique new drug with huge market demand and become an important breakthrough in the development of cloud medicine.
Deng Xianpei, secretary of the Communist Party of Chuxiong of the Communist Party of China, said that relying on the Peony brand, Chuxiong Prefecture has become one of the cities with the largest pharmaceutical production capacity in Yunnan Province except Kunming. Large companies are welcome to unite, reorganize and merge local pharmaceutical companies, increase industry concentration and market competitiveness, form a large enterprise-led approach, and coordinate the development of large and small enterprises, and realize the second venture of natural medicine.
According to the plans of the Chuxiong Economic Commission and the State Natural Pharmaceutical Office, Chuxiong will focus on the cultivation of Panlong Yunhai, Taiyang Pharmaceutical, Jinbi Pharmaceutical, Laojin Yuntang, and Longfa Pharmaceutical, etc. Business. Efforts have been made to create 10 special varieties such as detoxifying beauty capsules, compound agri-grass enteritis capsules, and old dialing Yuntang series, achieving sales revenue of about 5 million yuan for products and 2-3 million yuan for sales of 2-3 products.
Brands and Features are Equally Important Through inspections, the “pharmaceutical bosses†proposed suggestions for the development of ethnic medicine in Yunnan. Wu Zhijun, deputy general manager of Harbin Pharmaceutical Group, said that the most important thing for Harbin Pharmaceuticals is to have a brand. The medicine should be like a Tibetan medicine study, and expand the influence of the drug.
"The development of ethnic medicine must highlight its characteristics and make it perfect, and it will be possible to have a place in China and the world," said Liu Keliang, director of the Institute of Pharmacy of the Academy of Military Medical Sciences.
Sun Yaozhi, chairman of Henan Wanxi Pharmaceutical Co., Ltd., believes that the health of China’s 1.3 billion people should be mainly prevention, not after illness, so Yunnan ethnic drugs can do a lot to prevent and treat diseases.
“Yunyao cannot produce damage from the start of planting. From cultivation, decoction pieces, preparations to extraction of effective ingredients, a complete industrial chain must be developed. In addition, the characteristics of Yunyao in ethnic medicine do not come into play. One of the reasons is that It is not doing well in marketing,†said Tao Zhaohui, assistant to the president of Shanghai Fosun Pharmaceutical Group Co., Ltd.
More than 30 CEOs of domestic pharmaceutical companies participating in the “Healthy China 2020 Strategic Plan†National Pharmaceutical Industry Policy Seminar have also become the focus of the second venture of Peony Medicine. Panlong Yunhai hopes to seek cooperation with domestic large-scale chain-operating companies with strong strength and large scale of operations; Jinbi Pharmaceutical hopes to cooperate with domestic and foreign pharmaceutical and sales companies and adopt various forms of equity cooperation such as capital injection.
“For instance, Lao Dian Yun Tang has a long history, but the company only has more than 200 people. The human resources in marketing are obviously insufficient. The national culture is not well integrated with the national drug marketing. These long history and moving stories can be used for marketing packaging. Tao Zhaohui, assistant to president of Shanghai Fosun Pharmaceutical Group Co., Ltd., believes.
Yunnan ethnic pharmaceutical companies also took the opportunity to “throw the ball of hydrangeaâ€, and some companies also showed their intention of further cooperation.
There is a lack of clustering effect of Yunyao medicine. “The development of natural plant medicines in the world is in the ascendant, and the global market for natural botanical medicines is growing at a rate of 20% every year. This is a good opportunity for Yunyao's “Quick Horseâ€. More than 5,000 of the country’s production Among the kinds of drugs, there are more than 3,500 species involved in Yunnan botanical raw materials. Yunnan has a clear advantage in the development of botanical drug industry, and natural medicines based on plant extracts are the most potential and competitive advantages of Yunyao Pharmaceuticals. Direction.†Sun Xueming, director of Yunnan Food and Drug Administration, said.
The number of medicinal resources in Yunnan ranks first in the country, laying a good foundation for Yunnan's development of a cloud-drug industry dominated by natural medicine. At present, the rapid development of pharmaceutical industry and biomedical development in Yunnan Province, Yunnan Baiyao series, Panax notoginseng saponins series, artemisinin and artemether series, breviscapine series products, have a great impact in the country.
However, serious shortage of R&D investment, shortage of talents, irrational structure, severely lagging in standard research, and severe destruction of natural medicine resources are the most pressing difficulties for the development of cloud pharmaceutical industry. In particular, the corporate structure is irrational, polarization is severe, and profitability is low. Most enterprises are in a state of slight surplus or loss.
Up till now, only the production value of Yunnan Baiyao Group Co., Ltd. has reached a level of RMB 1 billion in the entire cloud pharmaceutical industry, and there are only five Yunpu Pharmaceutical manufacturers with an output value of RMB 200 million. In general, the status of the cloud pharmaceutical industry can be attributed to being small, scattered, weak, and miscellaneous. The degree of concentration is not high. There is no scale, no manifestation of the effectiveness of the cluster is the current "killing injury" cloud medicine. Take Xiong Yao as an example, the total amount of Chuxiong's natural medicine industry is small, and its industrial support ability is weak. The capacity for independent innovation is weak, and there are fewer independent branded products. In addition to the detoxification and nourishing capsules, there is not a batch of brands with good economic benefits.
The 20 billion target was initially set to expand and strengthen the cloud pharmaceutical industry, turning its resource advantage into a market advantage. Yunnan proposed to build the cloud pharmaceutical industry as if it were building a cloud tobacco industry. According to the development goals of Yunyao Pharmaceutical, by 2012, Yunpai will achieve a production value of over 20 billion yuan and become the most promising pillar industry.
How to divide cloud medicine cake? More than 70% of the province's pharmaceutical industry gathers in Kunming. The leading pharmaceutical companies in the province are highly concentrated. Based on this, Kunming City pioneered the clarion call of the “second venture†of the Yunyao Pharmaceutical Industry and proposed that by 2020, it will build the pharmaceutical industry into Kunming’s most important high-tech industry and become the country’s most distinctive pharmaceutical industry base; by 2012 We will strive to nurture 10 single-products with annual sales income of over 100 million yuan and 10 national and provincial-level well-known pharmaceutical brands. In this way, by 2012, Kunming plans to cultivate at least two pharmaceutical companies with sales revenues of more than 3 billion yuan each year, and more than five pharmaceutical companies with sales revenue exceeding one billion yuan, and 30 companies with sales revenue exceeding one hundred million yuan.
With the cultivation area of ​​31,230 mu of traditional Chinese medicinal materials and 964.07 tons of traditional Chinese medicine, Chuxiong is not far behind. After four years, it will use four years of time to attract investment, enrich the production and processing capacity of the pharmaceutical industry, and establish a brand name of “Sao Yaoâ€. Fully integrated into the “Sino-Indonesia Chinese Medicine Industry Beltâ€, it will eventually become the sub-center and core area of ​​the Suizhong Belt, and by 2020 it will reach a scale of more than 10 billion yuan, becoming a “hometown of drugs†and a traditional Chinese medicine valley.
"National Card" will become a breakthrough and the "national card" is the unique development direction of Yunnan. Yunnan has a large number of ethnic groups and has gradually formed a unique Yunyao culture system that is supplemented by minority medicine, Hanzi Tibetan medicine, and Miao Zhuang Naxi. There are more than 1,300 kinds of medicinal materials recorded by various ethnic groups and more than 10,000 non-governmental prescriptions. Many of them have unique features and are the source of new drug research and development. Digging, sorting, and developing national medicines will create a unique new drug with huge market demand and become an important breakthrough in the development of cloud medicine.
Deng Xianpei, secretary of the Communist Party of Chuxiong of the Communist Party of China, said that relying on the Peony brand, Chuxiong Prefecture has become one of the cities with the largest pharmaceutical production capacity in Yunnan Province except Kunming. Large companies are welcome to unite, reorganize and merge local pharmaceutical companies, increase industry concentration and market competitiveness, form a large enterprise-led approach, and coordinate the development of large and small enterprises, and realize the second venture of natural medicine.
According to the plans of the Chuxiong Economic Commission and the State Natural Pharmaceutical Office, Chuxiong will focus on the cultivation of Panlong Yunhai, Taiyang Pharmaceutical, Jinbi Pharmaceutical, Laojin Yuntang, and Longfa Pharmaceutical, etc. Business. Efforts have been made to create 10 special varieties such as detoxifying beauty capsules, compound agri-grass enteritis capsules, and old dialing Yuntang series, achieving sales revenue of about 5 million yuan for products and 2-3 million yuan for sales of 2-3 products.
Brands and Features are Equally Important Through inspections, the “pharmaceutical bosses†proposed suggestions for the development of ethnic medicine in Yunnan. Wu Zhijun, deputy general manager of Harbin Pharmaceutical Group, said that the most important thing for Harbin Pharmaceuticals is to have a brand. The medicine should be like a Tibetan medicine study, and expand the influence of the drug.
"The development of ethnic medicine must highlight its characteristics and make it perfect, and it will be possible to have a place in China and the world," said Liu Keliang, director of the Institute of Pharmacy of the Academy of Military Medical Sciences.
Sun Yaozhi, chairman of Henan Wanxi Pharmaceutical Co., Ltd., believes that the health of China’s 1.3 billion people should be mainly prevention, not after illness, so Yunnan ethnic drugs can do a lot to prevent and treat diseases.
“Yunyao cannot produce damage from the start of planting. From cultivation, decoction pieces, preparations to extraction of effective ingredients, a complete industrial chain must be developed. In addition, the characteristics of Yunyao in ethnic medicine do not come into play. One of the reasons is that It is not doing well in marketing,†said Tao Zhaohui, assistant to the president of Shanghai Fosun Pharmaceutical Group Co., Ltd.
More than 30 CEOs of domestic pharmaceutical companies participating in the “Healthy China 2020 Strategic Plan†National Pharmaceutical Industry Policy Seminar have also become the focus of the second venture of Peony Medicine. Panlong Yunhai hopes to seek cooperation with domestic large-scale chain-operating companies with strong strength and large scale of operations; Jinbi Pharmaceutical hopes to cooperate with domestic and foreign pharmaceutical and sales companies and adopt various forms of equity cooperation such as capital injection.
Rp 300 Graphite Electrode,300Mm Diameter Graphite Electrode,Eaf Lf Graphite Electrode,Low Price Graphite Electrodes
Carbographite Industrial PTE.LTD , https://www.graphites.pl